CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
+13.85%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$1.72B
AUM Growth
+$1.72B
(-6.8%)
Cap. Flow
-$378M
Cap. Flow
% of AUM
-21.9%
Top 10 Holdings %
Top 10 Hldgs %
60.63%
Holding
38
New
4
Increased
8
Reduced
6
Closed
9
Top Buys
| 1 |
DaVita
DVA
|
$72.3M |
| 2 |
Teva Pharmaceuticals
TEVA
|
$54.9M |
| 3 |
Bristol-Myers Squibb
BMY
|
$52.5M |
| 4 |
Ascendis Pharma
ASND
|
$50.6M |
| 5 |
AGN
Allergan plc
AGN
|
$43.9M |
Top Sells
| 1 |
TSRO
TESARO, Inc.
TSRO
|
$208M |
| 2 |
McKesson
MCK
|
$96.7M |
| 3 |
CELG
Celgene Corp
CELG
|
$96.1M |
| 4 |
GSK
GSK
|
$76.4M |
| 5 |
ELGX
Endologix Inc
ELGX
|
$55.3M |
Sector Composition
| 1 | Healthcare | 93.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $190M | 9.48% | 1,300,000 +300,000 | +30% | +$43.9M |
|
2
Viatris
VTRS
$12.3B
| $163M | 8.12% | 5,750,000 +750,000 | +15% | +$21.3M |
|
3
Perrigo
PRGO
$3.27B
| $101M | 5.04% | 2,100,000 -100,000 | -5% | -$4.82M |
|
|
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $95.3M | 4.75% | 1,800,000 -450,000 | -20% | -$23.8M |
|
5
Biogen
BIIB
$19.4B
| $94.6M | 4.71% | 400,000 +150,000 | +60% | +$35.5M |
|
6
Universal Health Services
UHS
$11.6B
| $87M | 4.33% | 650,000 -250,000 | -28% | -$33.4M |
|
|
7
DaVita
DVA
$9.85B
| $81.4M | 4.06% | 1,500,000 +1,332,472 | +795% | +$72.3M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $81.1M | 4.04% | 600,000 | – | – |
|
9
Atara Biotherapeutics
ATRA
$84.6M
| $79.5M | 3.96% | 2,000,000 +100,000 | +5% | +$3.98M |
|
10
Brookdale Senior Living
BKD
$1.83B
| $72.4M | 3.61% | 11,000,000 +3,500,000 | +47% | +$23M |
|
|
MDCO
11
DELISTED
Medicines Co
MDCO
| $69.1M | 3.44% | 2,471,523 +471,523 | +24% | +$13.2M |
|
12
Nektar Therapeutics
NKTR
$568M
| $67.2M | 3.35% | 2,000,000 | – | – |
|
13
Sarepta Therapeutics
SRPT
$1.78B
| $59.6M | 2.97% | 500,000 +150,000 | +43% | +$17.9M |
|
|
MNTA
14
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $58.1M | 2.9% | 4,000,000 | – | – |
|
|
15
Teva Pharmaceuticals
TEVA
$21.1B
| $54.9M | 2.73% | +3,500,000 | New | +$54.9M |
|
|
16
Bristol-Myers Squibb
BMY
$96B
| $52.5M | 2.61% | +1,100,000 | New | +$52.5M |
|
|
17
Ascendis Pharma
ASND
$11.8B
| $50.6M | 2.52% | +430,000 | New | +$50.6M |
|
18
Tenet Healthcare
THC
$16.3B
| $50.5M | 2.51% | 1,750,000 -1,500,000 | -46% | -$43.3M |
|
|
NUVA
19
DELISTED
NuVasive, Inc.
NUVA
| $42.6M | 2.12% | +750,000 | New | +$42.6M |
|
|
THOR
20
DELISTED
Synthorx, Inc. Common Stock
THOR
| $37.9M | 1.89% | 1,862,116 | – | – |
|
|
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
| $37.2M | 1.86% | 1,500,000 -1,300,000 | -46% | -$32.3M |
|
22
Zymeworks
ZYME
$1.12B
| $35M | 1.75% | 2,166,000 | – | – |
|
|
AMAG
23
DELISTED
AMAG Pharmaceuticals, Inc.
AMAG
| $34.1M | 1.7% | 2,650,000 | – | – |
|
|
EGRX
24
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $14.7M | 0.73% | 291,600 | – | – |
|
25
Sutro Biopharma
STRO
$72.7M
| $6.83M | 0.34% | 600,000 | – | – |
|